Literature DB >> 22020111

Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation.

Brooks M Hybertson1, Bifeng Gao, Swapan K Bose, Joe M McCord.   

Abstract

For the past 40 years or so, oxidative stress has been increasingly recognized as a contributing factor in aging and in various forms of pathophysiology generally associated with aging. Our view of oxidative stress has been largely "superoxide-centric", as we focused on the pathological sources of this oxygen-derived free radical and the types of molecular havoc it can wreak, as well as on the protection provided by the antioxidant enzymes, especially the superoxide dismutases, catalases, and glutathione peroxidases. In the last decade our view of oxidative stress has broadened considerably, and it is now often seen as an imbalance that has its origins in our genes, and the ways in which gene expression is regulated. At the center of this new focus is the transcription factor called nuclear factor (erythroid-derived 2)-like 2, or Nrf2. Nrf2 is referred to as the "master regulator" of the antioxidant response, modulating the expression of hundreds of genes, including not only the familiar antioxidant enzymes, but large numbers of genes that control seemingly disparate processes such as immune and inflammatory responses, tissue remodeling and fibrosis, carcinogenesis and metastasis, and even cognitive dysfunction and addictive behavior. Thus, the dysregulation of Nrf2-regulated genes provides a logical explanation for the connections, both direct and indirect, between observable oxidative stress and perhaps 200 human diseases involving these various physiological processes, each reflecting a network involving many gene products. The evolutionary self-association of these many genes under the common control of Nrf2 suggests that the immune and inflammatory systems may present the largest demand for increased antioxidant protection, apart from constitutive oxidative stress resulting from mitochondrial oxygen consumption for metabolic purposes. Gene expression microarray data on human primary vascular endothelial cells and on the SK-N-MC human neuroblastoma-derived cell line have been obtained in response to the dietary supplement Protandim, a potent composition of highly synergistic phytochemical Nrf2 activators. Pathway analysis of results shows significant modulation by Protandim of pathways involving not only antioxidant enzymes, but of those related to colon cancer, cardiovascular disease, and Alzheimer disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020111     DOI: 10.1016/j.mam.2011.10.006

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  247 in total

1.  NRF2 activation with Protandim attenuates salt-induced vascular dysfunction and microvascular rarefaction.

Authors:  Jessica R C Priestley; Katie E Fink; Joe M McCord; Julian H Lombard
Journal:  Microcirculation       Date:  2019-06-19       Impact factor: 2.628

Review 2.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

3.  Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice.

Authors:  Zhigang Wang; Xiaobing Dou; Songtao Li; Ximei Zhang; Xinguo Sun; Zhanxiang Zhou; Zhenyuan Song
Journal:  Hepatology       Date:  2014-02-25       Impact factor: 17.425

4.  Differential effects of vitamin C or protandim on skeletal muscle adaptation to exercise.

Authors:  Danielle R Bruns; Sarah E Ehrlicher; Shadi Khademi; Laurie M Biela; Frederick F Peelor; Benjamin F Miller; Karyn L Hamilton
Journal:  J Appl Physiol (1985)       Date:  2018-06-01

5.  Marine Natural Product Honaucin A Attenuates Inflammation by Activating the Nrf2-ARE Pathway.

Authors:  Samantha J Mascuch; Paul D Boudreau; Tristan M Carland; N Tessa Pierce; Joshua Olson; Mary E Hensler; Hyukjae Choi; Joseph Campanale; Amro Hamdoun; Victor Nizet; William H Gerwick; Teresa Gaasterland; Lena Gerwick
Journal:  J Nat Prod       Date:  2017-12-07       Impact factor: 4.050

6.  Combination of quercetin, cinnamaldehyde and hirudin protects rat dorsal root ganglion neurons against high glucose-induced injury through Nrf-2/HO-1 activation and NF-κB inhibition.

Authors:  Yue Shi; Xiao-Chun Liang; Hong Zhang; Qing Sun; Qun-Li Wu; Ling Qu
Journal:  Chin J Integr Med       Date:  2017-09-02       Impact factor: 1.978

7.  Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy.

Authors:  Micaela Johanna Glat; Nadia Stefanova; Gregor Karl Wenning; Daniel Offen
Journal:  J Neural Transm (Vienna)       Date:  2020-02-17       Impact factor: 3.575

8.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Authors:  Cliona Stack; Shari Jainuddin; Ceyhan Elipenahli; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Mariona Jové; Manuel Portero-Otin; Nathalie Launay; Aurora Pujol; Navneet Ammal Kaidery; Bobby Thomas; Davide Tampellini; M Flint Beal; Magali Dumont
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

9.  SMER28 Attenuates Dopaminergic Toxicity Mediated by 6-Hydroxydopamine in the Rats via Modulating Oxidative Burdens and Autophagy-Related Parameters.

Authors:  Shahram Darabi; Ali Noori-Zadeh; Farzad Rajaei; Hojjat Allah Abbaszadeh; Salar Bakhtiyari; Navid Ahmady Roozbahany
Journal:  Neurochem Res       Date:  2018-10-04       Impact factor: 3.996

10.  PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.

Authors:  Noel A Warfel; Alva G Sainz; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.